Huanjia Zhang

Articles Authored by Huanjia Zhang
Thermo Fisher Scientific Lowers 2025 Adjusted EPS Guidance in Light of Tariffs, US Policy Changes
Premium
The new guidance reflects the impact from China-related tariffs as well as dampening US grant funding, partially offset by the firm's mitigation actions.
GeneDx to Offer Genome Interpretation as a Standalone Service Following Fabric Genomics Acquisition
Premium
GeneDx, which has been running a centralized lab, hopes to provide the new service to hospitals in the US and abroad that are already sequencing genomes in-house.
MicroGen Dx, Labor Dr. Fenner Partner for Rapid Microbial DNA Sequencing Service in Europe
The service, aimed at healthcare professionals in Europe, promises to deliver diagnostic reports of microbial profiles within three to five days.
The clinical genetic testing company's Q4 revenues jumped 64 percent year over year to $95.6 million, driven by its strong exome and whole-genome testing business.
Adaptive Bio 'Confident' of MRD Reaching Profitability in 2025 as Q4 Revenues Rise 4 Percent
Premium
The Seattle-based firm booked $47.5 million in revenues during the fourth quarter while full-year revenues grew 5 percent to $179.0 million.
The company reported a 5 percent increase in Q4 2024 revenues and flat full-year revenues, but guided for 3 percent to 4 percent organic revenue growth in 2025.
Through close collaboration of more than 300 genomics and disease experts, the pan-European consortium solved more than 500 difficult cases.
The University of Edinburgh spinout is leveraging an RNA normalization technology and analysis software to detect breast cancer early.
GeneDx Stock Soars as Firm Reports 44 Percent Revenue Growth, $1.2M Adjusted Net Income in Q3
Premium
Revenues in the third quarter were driven by diagnostic exome and genome tests, which grew 76 percent in revenue and 46 percent in volume, prompting the firm to raise its 2024 guidance.
The company booked $10.60 billion in Q3 revenues, with flat year-over-year organic and core organic revenues.